Teehan Brendan 4

4 · ACADIA PHARMACEUTICALS INC · Filed Mar 27, 2024

Form 4

Period: 2024-03-25

EVP, COO, Head of Commercial

Transactions

Sale
Common Stock
2024-03-27$17.90/sh−5,140$92,006→ 36,340 total
Award
Common Stock
2024-03-25+10,048→ 41,480 total
Award
Stock Options (Right to Buy)
2024-03-25+89,516→ 89,516 total
Exercise: $17.84Exp: 2034-03-24→ Common Stock (89,516 underlying)
Award
Restricted Stock Units
2024-03-25+27,460→ 27,460 total
→ Common Stock (27,460 underlying)

Footnotes (5)

[F1]Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target.
[F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
[F3]25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
[F4]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F5]The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Documents

1 file